Fecal Microbiota Transplant Resources

FMT introduces microbes from a carefully screened donor’s stool into your digestive tract to help restore balance to your gut microbiome. By replenishing beneficial microbes, crowding out harmful ones, or sometimes even just by changing the balance, FMT may support healing in conditions such as recurrent C difficile (C. diff) colitis, inflammatory bowel disease (IBD), and other conditions.

• Home FMT: Some people perform FMT at home after acquiring the necessary equipment, using stool from a carefully screened donor sourced from their local community.
• Prescription and clinical FMT: There are FMT capsule and enema products licensed as drugs in the United States, for the purpose of preventing recurrent C. diff infections. There are other clinics and hospitals who prepare FMT products in-house for that purpose, which is approved under FDA guidelines as well. FMT products licensed as drugs can be used off-label for other conditions as well, although they are not covered by insurance for other purposes, and their cash prices are very expensive.
• International FMT: FMT is regulated different in some other countries, and there are quality clinics we sometimes refer to for that purpose
• Clinical trials: There are hundreds of clinical trials studying FMT for a variety of conditions - if your condition is being studied in a trial that is actively enrolling, you could participate!

No, we don’t perform FMT. Instead, we provide education, resources, and guidance to help you explore where FMT is available and whether it may be right for you.

Yes. As part of our educational visits, we can guide you on how to properly screen a donor and prepare for home FMT safely.

That depends on your condition, your symptoms, and your microbiome. We’ll discuss whether FMT could be indicated for you. There are no guarantees that you will benefit from FMT.

While not exhaustive, this list includes some of the most commonly studied conditions:

• C difficile (C. diff) infections.  FMT is highly effective and FDA-approved primarily for treating recurrent C. difficile colitis, often after antibiotic treatment failure.¹
• Inflammatory bowel disease (IBD)²
• Neurologic conditions such as multiple sclerosis (MS)^3–6, Parkinson’s disease⁷, amyotrophic lateral sclerosis (ALS^8,9), and autism^10,11.
• Metabolic disorders, including:
• Type 1 diabetes^12,13
• Type 2 diabetes (T2DM)^14,15
• Nonalcoholic fatty liver disease (NAFLD)¹⁶

When performed with a properly screened donor and safe preparation practices, FMT is considered very safe.

• Mild abdominal discomfort is the most common side effect.
• As many as 2-5% of people with IBD may experience a flare after FMT.¹⁷
• Most side effects are self-limited, and improve within one week.

1. Núñez F. P, Quera R, Bay C, Thomson P. Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases. Gastroenterología y Hepatología (English Edition). 2022;45(3):223-230. doi:10.1016/J.GASTRE.2021.05.005
2. Tan XY, Xie YJ, Liu XL, Li XY, Jia B. A Systematic Review and Meta-Analysis of Randomized Controlled Trials of Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease. Evid Based Complement Alternat Med. 2022;2022:8266793. doi:10.1155/2022/8266793
3. Laeeq T, Vongsavath T, Tun KM, Hong AS. The Potential Role of Fecal Microbiota Transplant in the Reversal or Stabilization of Multiple Sclerosis Symptoms: A Literature Review on Efficacy and Safety. Microorganisms. 2023;11(12):2840. doi:10.3390/MICROORGANISMS11122840/S1
4. Laeeq T, Vongsavath T, Tun KM, Hong AS. The Potential Role of Fecal Microbiota Transplant in the Reversal or Stabilization of Multiple Sclerosis Symptoms: A Literature Review on Efficacy and Safety. Microorganisms. 2023;11(12):2840. doi:10.3390/MICROORGANISMS11122840/S1
5. UCSF Multiple Sclerosis Trial → Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis. Accessed September 10, 2025. https://clinicaltrials.ucsf.edu/trial/NCT03594487
6. Laeeq T, Vongsavath T, Tun KM, Hong AS. The Potential Role of Fecal Microbiota Transplant in the Reversal or Stabilization of Multiple Sclerosis Symptoms: A Literature Review on Efficacy and Safety. Microorganisms. 2023;11(12):2840. doi:10.3390/MICROORGANISMS11122840/S1
7. Chen K, Sun L, Liu Y, Chen R. Safety and efficacy of fecal microbiota transplantation in the treatment of Parkinson’s disease: a systematic review of clinical trials. Front Neurosci. 2025;19:1639911. doi:10.3389/FNINS.2025.1639911
8. Yan J, Chen H, Zhang Y, et al. Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis. Gut Microbes. 2024;16(1):2353396. doi:10.1080/19490976.2024.2353396
9. Yan J, Yang Y, Cui J, et al. IDDF2024-ABS-0384 Efficacy and safety of fecal microbiota transplantation in amyotrophic lateral sclerosis. Gut. 2024;73(Suppl 2):A366-A367. doi:10.1136/GUTJNL-2024-IDDF.324
10. Zhang J, Zhu G, Wan L, et al. Effect of fecal microbiota transplantation in children with autism spectrum disorder: A systematic review. Front Psychiatry. 2023;14:1123658. doi:10.3389/FPSYT.2023.1123658/FULL
11. Li Y, Xiao P, Ding H, et al. Fecal Microbiota Transplantation in Children with Autism. Neuropsychiatr Dis Treat. 2024;20:2391-2400. doi:10.2147/NDT.S488001
12. Zhang S, Deng F, Chen J, et al. Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes: A systematic review. Front Cell Infect Microbiol. 2022;12:1075201. doi:10.3389/FCIMB.2022.1075201/XML
13. De Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial. Gut. 2021;70(1):92-105. doi:10.1136/GUTJNL-2020-322630
14. Aslam MR, Perala A, Wishart A V., et al. Therapeutic Potential of Fecal Microbiota Transplantation in Type 2 Diabetes Mellitus: A Systematic Review. Cureus. 2024;16(10). doi:10.7759/CUREUS.70642
15. Wu Z, Zhang B, Chen F, et al. Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study. Front Cell Infect Microbiol. 2023;12:1089991. doi:10.3389/FCIMB.2022.1089991/BIBTEX
16. Xue L, Deng Z, Luo W, He X, Chen Y. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Front Cell Infect Microbiol. 2022;12:759306. doi:10.3389/FCIMB.2022.759306/BIBTEX
17. Qazi T, Amaratunga T, Barnes EL, Fischer M, Kassam Z, Allegretti JR. The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes. 2017;8(6):574-588. doi:10.1080/19490976.2017.1353848